866.72 9.52 (1.11%) | 02-19 15:59 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 1038.77 | 1-year : | 1213.28 |
Resists | First : | 889.35 | Second : | 1038.77 |
Pivot price | 847.42 ![]() |
|||
Supports | First : | 787.79 | Second : | 725.01 |
MAs | MA(5) : | 862.34 ![]() |
MA(20) : | 831.52 ![]() |
MA(100) : | 824.2 ![]() |
MA(250) : | 829.92 ![]() |
|
MACD | MACD : | 21.7 ![]() |
Signal : | 19.9 ![]() |
%K %D | K(14,3) : | 65.7 ![]() |
D(3) : | 71.2 ![]() |
RSI | RSI(14): 61.7 ![]() |
|||
52-week | High : | 972.53 | Low : | 711.4 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ LLY ] has closed below upper band by 32.2%. Bollinger Bands are 2.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 863.69 - 868.53 | 868.53 - 872.96 |
Low: | 838.39 - 844.82 | 844.82 - 850.7 |
Close: | 847.97 - 857.2 | 857.2 - 865.66 |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Wed, 19 Feb 2025
ELI LILLY & Co SEC 10-K Report - TradingView
Wed, 19 Feb 2025
Eli Lilly and Company (LLY) Slid as its GLP1 Revenue Missed Expectations - Insider Monkey
Tue, 18 Feb 2025
Eli Lilly and Company (NYSE:LLY) Trading Up 1.5% - Here's What Happened - MarketBeat
Tue, 18 Feb 2025
Lilly to participate in TD Cowen's 45th Annual Health Care Conference - PR Newswire
Tue, 18 Feb 2025
The Zacks Analyst Blog Highlights Apple, Eli Lilly, Shopify and ImmuCell - Yahoo Finance
Mon, 17 Feb 2025
Why Eli Lilly and Company (LLY) Is the Best Drug Stock to Buy Now - MSN
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NYSE
|
|
Sector:
Healthcare
|
|
Industry:
Drug Manufacturers - General
|
|
Shares Out | 899 (M) |
Shares Float | 897 (M) |
Held by Insiders | 0.3 (%) |
Held by Institutions | 83.3 (%) |
Shares Short | 6,770 (K) |
Shares Short P.Month | 6,100 (K) |
EPS | 11.73 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 15.81 |
Profit Margin | 23.5 % |
Operating Margin | 41.9 % |
Return on Assets (ttm) | 0 % |
Return on Equity (ttm) | 84 % |
Qtrly Rev. Growth | 44.7 % |
Gross Profit (p.s.) | 40.71 |
Sales Per Share | 50.08 |
EBITDA (p.s.) | 20.84 |
Qtrly Earnings Growth | 101.8 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | 73.71 |
PEG Ratio | 0 |
Price to Book value | 54.7 |
Price to Sales | 17.27 |
Price to Cash Flow | 0 |
Dividend | 1.29 |
Forward Dividend | 0 |
Dividend Yield | 0.1% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |